HomeGeneticsConditionHereditary antithrombin deficiency
Back to Condition
Hereditary antithrombin deficiency
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Hereditary antithrombin deficiency

Hereditary antithrombin deficiency is a blood clotting disorder that significantly increases the risk of developing abnormal blood clots, particularly in the deep veins of the legs and the lungs.

Overview

Hereditary antithrombin deficiency is a disorder of blood clotting. People with this condition are at higher than average risk for developing abnormal blood clots, particularly a type of clot that occurs in the deep veins of the legs, known as a deep vein thrombosis (DVT). Affected individuals also have an increased risk of developing a pulmonary embolism (PE), which is a clot that travels through the bloodstream and lodges in the lungs. In hereditary antithrombin deficiency, abnormal blood clots usually form only in veins, although they may rarely occur in arteries.

About half of people with hereditary antithrombin deficiency will develop at least one abnormal blood clot during their lifetime. These clots usually develop after adolescence.

Other factors can increase the risk of abnormal blood clots in people with hereditary antithrombin deficiency, including:

  • Increasing age
  • Surgery
  • Immobility
  • The presence of other inherited blood clotting disorders

Women with hereditary antithrombin deficiency are at increased risk of developing an abnormal blood clot during pregnancy or soon after delivery. They also may have an increased risk for pregnancy loss (miscarriage) or stillbirth.

Frequency

Hereditary antithrombin deficiency is estimated to occur in about 1 in 2,000 to 3,000 individuals. Of people who have experienced an abnormal blood clot, about 1 in 20 to 200 have hereditary antithrombin deficiency.

Causes

Hereditary antithrombin deficiency is caused by mutations in the SERPINC1 gene. This gene provides instructions for producing a protein called antithrombin (previously known as antithrombin III). This protein is found in the bloodstream and is important for controlling blood clotting by blocking the activity of proteins that promote blood clotting, especially a protein called thrombin.

Most mutations associated with this condition change single protein building blocks (amino acids) in antithrombin, which disrupts its ability to control blood clotting. Individuals with this condition do not have enough functional antithrombin to inactivate clotting proteins, resulting in an increased risk of developing abnormal blood clots.

Gene Associated with Hereditary Antithrombin Deficiency

  • SERPINC1

Inheritance

Hereditary antithrombin deficiency is typically inherited in an autosomal dominant pattern, which means one altered copy of the SERPINC1 gene in each cell is sufficient to cause the disorder. Inheriting two altered copies of this gene in each cell is usually incompatible with life; however, a few severely affected individuals have been reported with mutations in both copies of the SERPINC1 gene.

Other Names for This Condition

  • Antithrombin III deficiency
  • Congenital antithrombin III deficiency

Frequently Asked Questions

nticoagulation is typically started immediately after the event with heparin bridging to warfarin or a direct oral anticoagulant. The duration depends on the presence of provoking factors, the patient’s risk profile, and family history; many clinicians opt for at least 6–12 months, with consideration for lifelong therapy if recurrent risk remains high.
Because antithrombin is the natural inhibitor of thrombin and factor Xa, its deficiency reduces the effectiveness of heparin, requiring higher doses or monitoring of anti‑Xa levels. Warfarin dosing may also be more variable; frequent INR checks and dose adjustments are necessary to maintain therapeutic range.===
They should receive low‑dose heparin (unfractionated or low‑molecular‑weight) starting in the first trimester, continuing through delivery and the postpartum period. Close monitoring of anti‑Xa levels, blood pressure, and signs of thrombosis is essential. Early mobilization and avoidance of prolonged immobility are also advised.
Screening involves measuring plasma antithrombin activity and antigen levels. If reduced, genetic testing of the SERPINC1 gene is performed to detect pathogenic variants. Family members can be tested to determine carrier status and guide prophylaxis.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA